{"id":871579,"date":"2025-08-06T10:31:38","date_gmt":"2025-08-06T14:31:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/"},"modified":"2025-08-06T10:31:38","modified_gmt":"2025-08-06T14:31:38","slug":"belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/","title":{"rendered":"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Aug.  06, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pmILUix9AJie_P2oH5yk48dTes4saNw-iyKR2MuB1lxL-tJHW2Slri0jR6p3MsmBdADTNuqGl54aTE6apvhgRw==\" rel=\"nofollow\" target=\"_blank\">Belite Bio<\/a>, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">7:00 am ET, on-demand corporate presentation<\/li>\n<li style=\"text-align:justify\">11:00 am ET, \u201cPivotal-Stage Assets for Retinal Disorders\u201d panel discussion<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Webcast Link Instructions<\/strong><br \/>\n        <br \/>A webcast of each presentation can be accessed under the &#8220;Events&#8221; tab on the investor relations section of the Belite Bio website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FixF-8kbIYBWRiOXJZoQP1wtjRXv2w6kdwYyEtwyRlnPHxnFsVb1wIhpkHzeKVvZEn5XojlzZ0p9vdZPSWlOLsITHCAsOfpUmshT12o0NFW9YnwHfiA80D3ExNANL-ESeFfmG3uBt_gZt6o-mf8yj2skRtd0tFK3tYAjD-6IfEGMeBdNf7VpQrxMEKjMM9XUwed067bakfLxbRItRkO3zg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.belitebio.com\/presentations-events\/events<\/a>. The replays will be archived for 90 days following the presentation date.<\/p>\n<p align=\"justify\">\n        <strong>About Belite Bio<\/strong><br \/>\n        <br \/>Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite\u2019s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2\/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wQbW5srlNzbc95BXln9e80DZi4ZTwJZTn1BdxOx0aIn3KDK2BUFnIh06LsjNFSq4uF83ogQGcOCzyBcJv5C5D-tUAvZGDsV3c-ojmRM9dVcHvM_piM6bI-7kQ3k06Z8EgxpqRDoLnr2fARsVSZ_DDUtvManIZ71HEl90ntfkdSs6V8m_BJOEnpY5vZIDMxrRkilVbtHjsT4X-7QrcFG4qSRq55eDteNB7u8G1hvSQvkEEbmTASddb7s0_rA47GE5R3bZIXNDn0rcwaB48hU5vvv5ekmbmYnSb2nQDZrICmtp2Y6uxcq9xNC1u9IQP8UGGXrPhPQBRCFSQkSZI7PFSd5FcrKEgoS2OpfW72vsDD2A-wBVy1NCT3Nj3ttR89pS\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xO620cSG_JUf0zAoktbvsmLuQ5Z-aPv7oraWasYxzt6yb4RuOaD1E3MQsLghnU2QNCr8fdKoFygeWYMzjKc84A8PDkofhaX2CF5_psZz5k4PePHo94aWgIgRDP0v31x-9Es2SVAX6P4ZhbHdgN4nxRJGg367qyLwOHoTPvdfMpKn33POfCCGJIQONFpzxmNAN-2k_5socZyUxZjXSEoZGjEA8AH6bpW37diM6jjeC2EoLO370CJdQK-AmpBOMY3nFG7b5SxYrZusgmw3qGP3IlR-1UMq4ShipOFteAob5wemvNXlgs1tsLa9Mk_KB01dxPCmtddKWAGV40m_0kVIHtsdp-u3j9PPPcYX4VY9EeFM---UzkBcIpZK2GLk0p7rGB5CBKfGf0nvoQjZDy1yhwGC8N2EJnY0wfv7-lNsECp-xencwJe927_YwgLTE1a6N9_bGMf8uOHp1cKRRrLgCaEmd90lHO7ebAVXP1gZ90QXKvv0n1eLtQJZLHoK7gIG8A9tmwKUE_aXhaMSRTcbDY4cC9JEMZOoAjCGGLOKjzXUDlg88kV5A64l5KVwasJeg2NU1155B5Hf-Di1iai8_D-tI8EoayZjiREAUmphmkmXW9oBuWn2Ca05gIOI93fjxjGWVi26zy1fdk6NlhTSQd-NPHCohA2TUjPLilN_YzQHKhUJIO9q3O73s_YBkITugsO1JDH8E_KXXxODExihGIenihoA2vtMk3XlnXDtZ8wYsqcrZRGgpPy7l9FbLdyqqxnDHqHVFaPL2TaVRQFclRpYZgf4d9P_VQrBkZft8bu9aspIetx_vRO_uJQ9w8NeK9t-sMijigsaLQSyIJh--tDP5k1cv0G5f4kXZRQJ-G0tFBdeGCjf7kIQ9tMNN0FHC3Ww1HzGzThjG5npSKS2WB2PmIR0K8vaUboU71qghrjp9JBCTSfkDZ7fMV1lI22jJdpKFK1kYkGw8XKhPcHL5qKUXRF5jXjZaZF1LQ5RqcdTyMXmwM4q2h5H0jL1YSie3GWLqU6kOPKmCda5vRgfmQ==\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kI4SSWh5MYQpWbo9I7N4c8Fhrt-mRVyRqVNWf_ELbCUEF5APR8a8rC_oheNJCllj8IScgs198nPY6kayXLzPVr98-XP6LhwLOF_p-iOeUTqcj4F7HPEUdgSv16ZSkr6KDt5oD6I2q42xOvRw6eOcjNkcgX-S0NQqvRYwRjP2wIfPW7Oxg50NAyGGbBjmGAadnTfgis3-aSf6v2S9ZzwADZHwtPPpzhrW5YxPZwB25JhhyHkdih4t8lIoLR9MX85NYvysa2R3gzxHmmZcBBFp_bA8eeBXg9jLAeN4ZUWL58u2c6fem_Z6t2JiVtQnmS0RKQ2amEUfP3oeQvHV-aV-LJltdPE3mz_0jhUPQYVIEHyqJxdRNCMNCJ5XYtjp5Itr0JOggU_9tar9n6GVSsI5G52Q9A4IWklGVuihC9TnK8wiY8viduQNvsqXTIDG-cqPXc6REDFvz0TwJBsZAtF_r2DHs6jd7xlYIb-W44le4S2CgJStJsK_HqHQEyPqsNzYrZqSxTtxTXimSEDJmf1361VL5P6MKWKuHKX231I9y0mRRDruiySGRSFD5Ge_JfpqWs6d5tJNEAQSZkekVH9p0BRLynL8NZAjTCY5ha6bycXAqWKIed-mLltUagZWuOhFrtuhyzFvXWULXLUdG1A06KNUMRE87fd60VGAxAnug3AjPRa5TpP8h3-1TVuA4GVZVKKtFm67UyPei4woXlq2yqti7rvXETmWRnZ2BAEMYAzVFHfnwo7yoR3w92X7LWTY6sSICkNWlOS6bjQMuBh5zbvthIgEHYWBKw-uioPkqluV5xef9LDUrITcoMxnyP70AGF0hunxjuDC5uKJ6xZQJu38X17EpPeh0ldgD7W6zqOJB_7kLUUbah4To6ldvoEcik4xdyUL-KWaD5A4OMr2Gqb6e8kyazCnpxlp7RREmpDUdZJIhJcVM7Sf3a0rDmGW8EjIt1gVNtoH2g3QoyuT-T6UW043rBhMiOBNkP-DC9rFAVWnQVtcB_QU1C9Cgcqg3iYsQoFOAV54nLzCvwUNew==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eB8l2HrqLZXdxSKEFNZpYPkD5FudgwIQdax8TDVEBq8FtDjplCoupZsUGaFWZHuXpLYN2Mc5kTVwP2GBIXEAqchBlkIMJOZW302a2K31goRAfv1J7CDhR9gv1ktf_5MHEpn_1SWYTsPJSYne4OPpHQNS-Kxu4oep5o9uUO9C7JRUGzxuqtgqxE7EIxxmwuE1RYG7GsBnXAWf_j8OhKC3JP5Y8xBf-kKLn_nikEi-6XU9KEu7VEVLlA8eZiRX5Mxaqtu9TZWi0V1574EDg49yF7Tst5Qbq2raOVIbqhKAm45t63TJ2EAg7OpU6JxPnEuzusb6cUiPRrS_7QQ18XkVGcnC9WU1p_OxVkx_menCQL2JfIZhDZFgrS6wF3FBU9b_pUHaX7RO_KOzylR7CWYFcLmzAXxtm_iDafGFBRTMYe6n3bH9k1I-ma-ztt7SxdGG\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>\u00a0or visit us at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LUlffpeVhkiraV_TDWGt0MAhBy2x0U4SwZFbz9H6uaV4dNXHuObdQGKiFhRGFW4EplPubgdXfwyzQWSyc-NKnMLPHfZtpL4eTdhZ2dATNlQMZttAQlWnnqJLtY-LtiY3hjzewnXw5rF2Q0Wt318iHBS8wvOun_zMHX9NeCs-nulCtRF_9DpVHOTr_10etFhDIfz02aNItl8jYDu19bDvJzRMA8l9rjw69jjKBbONt3SFMO-iFxx7X6e4QR_ulG1Nu5_0-F9mhAooLepqtwWQnjoi9Xr38Mv4ifTqm-6Mt2m8qKyexURrTNHES9Y7eJsTZTKZm3yPqMHLmgnG3n1VzLUTIUkP7NC6ioz7FrLafrqIykF4t4sGh30DHVttfzoETGEUDsACpE1vUd1oBIADuXTR05FathmlroFuMnkSkBXJDFGxUIaZoXtl7PJA4Ik5zMG5K-_oQD_Gw-8090zhkij6GEuwnkA8IsspAJryiHYB1AA18M0CTJHqrije7nrHahtalMpw9Lipc7Morj3iSBB9dYyEe_9pF_NQ2kEwr8ymiu3O_Oi57kZTtIdk_NBAnI30MYPdqWET6o881iq0JDbEaHjEicdaCKurM9-0NP5T_G2IgHrxj81r_knsWK7_YLI4MxTDcAHhiJ48p7P0-JwZU_rRdemlnv4Vm9KgYDQz66g0K4i0w4rbHAUXaeL_qWfTLZR7YowS4qAZh2KTfwWyszG57w3-6FurEtpfU9bwrjAqfJO_puEsU-3P81poW3HzQyN1kz3bH1qjXtHFk4djpyMnw1dor2ZfvpO6xzKtIh-azIPajPebPY5rNWuHxTR5wJ49qKgWEl0AYT_rMYeINkAG5aRAxqrtkFDbkskeoxdogpqEjvqgZoPy41zOz41uMq6taCmTrFRvL2AOpK9dgU2edcfv7aVes0rthNOCVWX6NNu7Ifj0I_uTQiJctkPWM09fjI_dWuscxIvr9D6sK3pjqI9XXCHnwZREoVfIVcjzLcvkObjXcxkdMz0sWiyA3lqYE1SvgKnA1jWQg4CPhUxUG1NDGa9iZ2unEmtD3O37fLeAKpA88j5OAu_J8_g3HGQegxNi25DxhfWJqNsNcr5vuBByzJZp8ZFHBtU=\" rel=\"nofollow\" target=\"_blank\">www.belitebio.com<\/a>.<\/p>\n<p>\n        <strong>Media and Investor Relations Contact:<\/strong><br \/>\n        <br \/>Jennifer Wu <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_IBDFN4fqM_4nQkSZzbMIBFSSckLqcZsemRm3Xc3YyLII3ZVymRv5s9eQEZ1qixBPkXAuxOgHPo6iyi153BPaQIuDOIL-h8DN3818FLKJvk=\" rel=\"nofollow\" target=\"_blank\">ir@belitebio.com<\/a><\/p>\n<p>Julie Fallon<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zM92qi7FLOI5FqZqO2iEKPwo6CzghDbG1qGb-xYhWzITTwEPVECG8vMtj9KJsQdS6xjX7z1Ml6Pe4y0CSlzpQjW4etsFWstkIHDqf7MBfsPehOs1s8vP2RyJK3Q2rZsK\" rel=\"nofollow\" target=\"_blank\">belite@argotpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjUyMzc4YTQtMjZkZC00ODUyLWExYWYtYzJhOTg2ZGU0OGY2LTEyNDUyODUtMjAyNS0wOC0wNi1lbg==\/tiny\/Belite-Bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows: 7:00 am ET, on-demand corporate presentation 11:00 am ET, \u201cPivotal-Stage Assets for Retinal Disorders\u201d panel discussion Webcast Link Instructions A webcast of each presentation can be accessed under the &#8220;Events&#8221; tab on the investor relations section of the Belite Bio website at: https:\/\/investors.belitebio.com\/presentations-events\/events. The replays will be archived for 90 days following &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-871579","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows: 7:00 am ET, on-demand corporate presentation 11:00 am ET, \u201cPivotal-Stage Assets for Retinal Disorders\u201d panel discussion Webcast Link Instructions A webcast of each presentation can be accessed under the &#8220;Events&#8221; tab on the investor relations section of the Belite Bio website at: https:\/\/investors.belitebio.com\/presentations-events\/events. The replays will be archived for 90 days following &hellip; Continue reading &quot;Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-06T14:31:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference\",\"datePublished\":\"2025-08-06T14:31:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/\"},\"wordCount\":263,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/\",\"name\":\"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=\",\"datePublished\":\"2025-08-06T14:31:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference - Market Newsdesk","og_description":"SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows: 7:00 am ET, on-demand corporate presentation 11:00 am ET, \u201cPivotal-Stage Assets for Retinal Disorders\u201d panel discussion Webcast Link Instructions A webcast of each presentation can be accessed under the &#8220;Events&#8221; tab on the investor relations section of the Belite Bio website at: https:\/\/investors.belitebio.com\/presentations-events\/events. The replays will be archived for 90 days following &hellip; Continue reading \"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-06T14:31:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference","datePublished":"2025-08-06T14:31:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/"},"wordCount":263,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/","name":"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=","datePublished":"2025-08-06T14:31:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNjk5NSM3MDg0MTU2IzIyMzM3MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-h-c-wainwright-annual-ophthalmology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/871579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=871579"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/871579\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=871579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=871579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=871579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}